Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 495 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cortef Clear all
Withdrawn Phase 1 Interventional

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

NCT00957320
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Sirolimus, PEG-asparaginase
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

Effect of Hydrocortisone on the Brain

NCT00055003
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers

NCT03419871
View directory record Official record
Conditions
Sleep Disorder
Interventions
Monitoring Sleep, stress biomarkers
Other
Lead sponsor
Yale University
Other
Eligibility
12 Months to 15 Months
Enrollment
100 participants
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
Procedure · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Results available

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

NCT02289989
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oregano extract cream, Hydrocortisone
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

NCT02153762
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Locoid Lipocream, Hylatopic Plus
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00002805
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features

NCT01310140
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

NCT03307850
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Observation During Exercise and Stress
Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Santa Barbara, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Tracheostomy Granulomas

NCT02116608
View directory record Official record
Conditions
Granuloma, Tracheostomy
Interventions
Betadine, Silver Nitrate, Hydrocortisone Butyrate Cream, 1.0%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects

NCT01536925
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous Exenatide (Byetta) During Surgery

NCT00882050
View directory record Official record
Conditions
Euglycemia, Hypoglycemia, Hyperglycemia
Interventions
Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

NCT00953576
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, hydrocortisone, dutasteride, lapatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 24, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

NCT07763210
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
Interventions
Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide, Axicabtagene Ciloleucel, Brexucabtagene Autoleucel
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depression, Aging, Stress and Heart Health Study

NCT05570721
View directory record Official record
Conditions
Menopause, Depression, Heart Disease in Women, Stress
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

Hypotension in Neonates

NCT00882284
View directory record Official record
Conditions
Infant, Newborn, Hypotension, Blood Pressure
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

NCT00176462
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
aminopterin, L-asparaginase, cyclophosphamide, cytarabine, daunomycin, dexamethasone, 6-mercaptopurine, methotrexate, 6-thioguanine, vincristine, Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone), Leucovorin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
1 Year to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Neptune City, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

NCT02372110
View directory record Official record
Conditions
Anxiety
Interventions
HPA, ANS stimulation, Placebo
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

NCT00447473
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, Ketoconazole, Mitoxantrone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

NCT00673127
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone and Dutasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

NCT00003593
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 24, 2026, 4:15 PM EDT